Winselow Tucker

Winselow Tucker has extensive experience in the pharmaceutical industry, specifically in the field of oncology. Winselow is currently serving as the SVP and Chief Commercial Officer of Oncology at Loxo Oncology at Lilly since September 2022. Prior to this, they held various senior leadership roles at Bristol Myers Squibb, including Senior Vice President of Intercontinental from January 2022 to September 2022, and Senior Vice President and General Manager of US Hematology from November 2019 to January 2022. Winselow was responsible for the commercialization of Bristol Myers Squibb's Hematology portfolio, launching new therapies, and driving growth.

Before joining Bristol Myers Squibb, Winselow Tucker served as the Corporate Vice President and General Manager of US Hematology and Oncology at Celgene from July 2018 to November 2019. Winselow also worked at Novartis as the General Manager of Novartis Oncology, Canada, from January 2016 to July 2018, and as the Vice President of Global Product Strategy and Global Disease Lead for Breast Cancer from June 2014 to December 2015. Additionally, they held the position of VP Global Commercialization, Immuno-Oncology Strategy and Early Oncology Development at Bristol-Myers Squibb from October 2013 to June 2014.

Winselow Tucker began their career at Infinity Pharmaceuticals, where they served as the Vice President of Marketing from June 2010 to October 2013. Through their various roles, Winselow Tucker has gained expertise in commercialization, market access, and product strategy in the oncology field.

Winselow Tucker has a Bachelor of Business Administration (BBA) degree in Accounting from Howard University. Winselow also holds a Master of Business Administration (MBA) degree in Marketing and Finance from Indiana University - Kelley School of Business.